Patients Rising is helping cancer patients access precision medicine treatments with OncoPrecision, an online community developed with CancerConnect.com.
(Washington, D.C./Sun Valley, ID): Patients Rising has launched an online platform for cancer patients and caregivers to learn, connect and access the latest advances in precision medicine.
OncoPrecision will provide cancer patients and caregivers with daily news updates on developments in precision medicine, comprehensive background on drug information and resources for accessing clinical trials along with support from the largest dedicated cancer social community on the web.
“We are truly excited about this one-of-a-kind resource and are eager to do what it takes to put precision medicine where it can do the most good: in the hands of patients,” said Terry Wilcox, co-founder and executive director of Patients Rising. “OncoPrecision represents outstanding forward thinking and the highest ideals of patient advocacy, especially at a time when the promises of precision medicine are changing more and more lives every day.”
Helping Cancer Patients Access Precision Medicine Treatments
Precision medicine is expected to radically transform health care as we know it by providing patients with treatments that are personalized to each individual patient. Already, patients are benefiting from precision medicine treatments, such as immunotherapy, which harness the body’s immune system to fight diseases, including some cancers.
However, few cancer patients are aware of currently-available precision medicine treatment options –with even fewer patients able to gain access to these life-saving treatment innovations. OncoPrecision is working to close this precision medicine access gap by providing cancer patients and their caregivers a unique destination to seek and share information about the latest developments in precision medicine.
Created by CancerConnect, OncoPrecison will also provide members with the ability to interact with a broader national community of more than 50,000 cancer patients through the existing CancerConnectplatform. The platform will be used by the Dana-Farber Cancer Institute, Memorial Sloan-Kettering Cancer Center, Beth Israel, the National Ovarian Cancer Coalition The Ohio State James Cancer Hospital, Roswell Park, and Miami Cancer Institute at Baptist Health South Florida.
Tisotumab Vedotin – Promising in Advanced Cervical Cancer
Novel precision cancer medicine promising for treatment of advanced ovarian cancer.
Checkpoint Inhibitor Immunotherapy for Treatment of Advanced Cervical Cancer
Checkpoint inhibitor immunotherapy prolongs survival and delays recurrence in advanced cervical cancer.
Precision Antibody-drug conjugate promising in Ovarian Cancer
Learn about the STRO-002 Antibody-drug conjugate in Ovarian Cancer
“We are thrilled to partner with Patients Rising to help bring cancer patients news and information on the exciting innovation happening in precision medicine today,” said Charles Weaver, MD founder and executive editor of CancerConnect.com. “OncoPrecision represents outstanding forward thinking and the highest ideals of patient advocacy, especially at a time when the promises of precision medicine are changing more and more lives every day.”
Patients Rising, a leading patient advocacy organization, was formed to stand up for patients, advocate for their rights, and fight for their access to the medications they need and deserve.
CancerConnect.com, developed and managed by OMNI Health Media, is the largest dedicated cancer social community on the web in use at Memorial Sloan-Kettering Cancer Center, Roswell Park Cancer Institute, Dana-Farber Cancer Institute, The University of California, and The Ohio State James Cancer Hospital.
OMNI Health Media, an award-winning publisher of consumer health information, producesWomen magazineandThe Web Chats with the Expertsinteractive series. It has also developed the country’s leading health social communities, includingCancerConnect,theGIConnection,theRAConnection, andtheSpineCommunity.
Copyright © 2018 CancerConnect. All Rights Reserved.